GALERA THERAPEUTICS, INC. (GRTX): Price and Financial Metrics
GRTX Price/Volume Stats
| Current price | $0.19 | 52-week high | $3.59 |
| Prev. close | $0.20 | 52-week low | $0.09 |
| Day low | $0.17 | Volume | 4,160,500 |
| Day high | $0.21 | Avg. volume | 2,458,767 |
| 50-day MA | $0.20 | Dividend yield | N/A |
| 200-day MA | $0.50 | Market Cap | 10.12M |
GRTX Stock Price Chart Interactive Chart >
GALERA THERAPEUTICS, INC. (GRTX) Company Bio
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Latest GRTX News From Around the Web
Below are the latest news stories about GALERA THERAPEUTICS INC that investors may wish to consider to help them evaluate GRTX as an investment opportunity.
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesFDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se |
Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateFDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest gainers and losers this morning! |
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for AvasopasemMALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the Company’s New Drug Applica |
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceMALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:3 |
GRTX Price Returns
| 1-mo | -21.65% |
| 3-mo | 8.57% |
| 6-mo | -16.34% |
| 1-year | -93.19% |
| 3-year | -97.14% |
| 5-year | N/A |
| YTD | 30.67% |
| 2023 | -90.24% |
| 2022 | -67.54% |
| 2021 | -55.13% |
| 2020 | -22.26% |
| 2019 | N/A |
Loading social stream, please wait...